Matinas BioPharma Investor Presentation Deck
Compassionate Use - Recovery from IV Amphotericin B Kidney Toxicity with MAT2203
A 38 y/o female with systemic lupus erythematosus on chronic hydroxychloroquine and prednisone presented with a progressively enlarging wound on her left foot.
13
05/2022:
Initial admission
L achilles tendon debridement
L partial calcanectomy; Bone biopsy
Culture - Rhodotorula mucilaginosa
Creatinine (mg/dL)
1
0.8
0.6
0.4
0.2
4/1
2022
07/2022:
Patient admitted twice for dysgeusia,
nausea, vomiting, hypok, hypoMg
7
06/2022
7/1
IV Ampho-B
08/2022
Creatinine stabilized
10/1
Date
1/1
2023
11/2023:
MR foot without signs of active osteomyelitis
3/1
Oral MAT2203
Potassium (mmol/L)
5
0
4/1
2022
COPYRIGHT MATINAS BIOPHARMA 2024
K+repletion
7/1
01/2023
Potassium stabilized
10/1
Date
M
UNIVERSITY OF
MICHIGAN
04/2023:
Patient remains without signs of infection
1/1
2023
3/1
MATINAS
BIOPHARMAView entire presentation